Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer

Urology

Volumn 53, Issue 1, 1999, Pages 139-147

  Veltri, Robert W ^a   Miller, M Craig ^a   Zhao, Gang ^a   Ng, Angela ^a   Marley, Garry M ^a   Wright Jr, George L ^b   Vessella, Robert L ^c   Ralph, David ^a  

^a UroCor Incorporated   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; INTERLEUKIN-8; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RNA; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0032937653     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00455-5     Document Type: Article

References (36)

1. Wingo P.A., Landis S., Ries A.G. An adjustment to the 1997 estimate for new prostate cancer cases. Cancer. 80:1997;1810-1813.
2. Jacobson S.J., Katusic S.K., Bergstrlh E.J., et al. Incidence of prostate cancer diagnosis in eras before and after serum prostate specific antigen testing. J Am Med Assoc. 274:1995;1445-1449.
3. Babian J.R., Kojima M., Ramirez E.I., et al. Comparative analysis of prostate specific antigen and its indexes in detection of prostate cancer. J Urol. 156:1996;432-437.
4. McCormack R.T., Rittenhouse H.G., Finlay J.A., et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family a new era . Urology. 45:1995;729-744.
5. Soh S., Kattan M.J., Berkman S., et al. Has there been a recent shift in pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 157:1997;2212-2218.
6. Lithrup P.J., Kane R.A., Mettlin C.J., et al. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Detection Project. Cancer. 74:1994;3146-3150.
7. Ralph D., Veltri R.W. Serum biomarkers for prostate cancer update and future prospects . Adv Lab. 6:1997;51-56.
8. 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
9. Marley G.M., Miller M.C., Kattan M.W., et al. Free and complexed prostate specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology. 48:1996;16-22.
10. Partin A.W., Oesterling J.E. The clinical usefulness of free-PSA. Urology. 48:(suppl 6A):1996;1-3.
11. Orozco R., O'Dowd G.J., Kunnel B., et al. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 51:1998;186-195.
12. McClelland M., Ralph D., Cheng R., et al. Interactions among regulators of RNA abundance characterized using RNA fingerprinting by arbitrarily primed PCR. Nucleic Acids Res. 22:1994;4419-4431.
13. Mukaida N., Shiroo M., Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 143:1989;1366-1371.
14. Sidransky D. Molecular screening how long can we afford to wait? J Natl Cancer Inst. 86:1994;955-965.
15. Moreno J.G., Croce C.M., Fischer R., et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 52:1992;6110-6112.
16. Hebert C.A., Baker J.B. Interleukin-8 a review . Cancer Invest. 11:1993;743-750.
17. Villarete L.H., Remick D.G. Transcriptional and post-transcriptional regulation of interleukin-8. Am J Pathol. 149:1996;1685-1693.
18. Watson J.M., Kingston D.G., Chordia M.D., et al. Identification of structural region of taxol that may be responsible for cytokine gene induction and cytotoxicity in human ovarian cancer cells. Cancer Chemother Pharmacol. 41:1998;391-397.
19. McColl S.R., Roberge C.J., Larochelle B., et al. EBV induces the production and release of IL-8 and macrophage inflammatory protein-1 alpha in human neutrophils. J Immunol. 159:1997;6164-6168.
20. Greiffenberg L., Sokolovic Z., Schnittler H.J., et al. Listeria monocytogenes-infected human umbilical vein endothelial cells internalin-independent invasion, intracellular growth, movement, and host cell responses . FEMS Microbiol Lett. 157:1997;163-170.
21. Chaudhary L.R., Avioli L.V. Regulation of interleukin-8 gene expression by interleukin-1B, osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells. J Biol Chem. 271:1996;16591-16596.
22. Fujisawa H., Wang B., Sauder D.N., et al. Effects of interferons on the production of interleukin-6 and interleukin-8 in human keratinocytes. J Interferon Cytokine Res. 17:1997;347-353.
23. Badolato R., Ponzi A.N., Millesimo M., et al. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood. 90:1997;2804-2809.
24. Kumar N.M., Rabadi N.H., Sigurdson L.S., et al. Induction of interleukin-1 and interleukin-8 mRNAs and proteins by TGF beta 1 in rat lung alveolar epithelial cells. J Cell Physiol. 169:1996;186-199.
25. Makarov S.S., Johnston W.N., Olsen J.C., et al. NF-Kappa B as a target for anti-inflammatory gene therapy suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA . Gene Ther. 4:1997;846-852.
26. Seitz M., Loetscher P., Dewald B., et al. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol. 23:1996;1512-1516.
27. Shute J.K., Vrugt B., Lindley I.J., et al. Free and complexed interleukin-8 in blood and bronchial mucosa in asthma. Am J Respir Crit Care Med. 155:1997;1877-1883.
28. Abruzzo L., Thornton A., Liebert M., et al. Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. Am J Pathol. 140:1992;365-373.
29. Scheibenbogen C., Mohler T., Haefele J., et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumor load. Melanoma Res. 5:1995;179-181.
30. Singh R.K., Gutman M., Radinsky R., et al. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res. 54:1994;3242-3247.
31. Ueda T., Shimada E., Urakawa T. Serum levels of cytokines in patients with colorectal cancer possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis . J Gastroenterol. 29:1994;423-429.
32. Ferrer F.A., Miller L.J., Andrawis R.I., et al. Angiogenesis and prostate cancer in vivo and in vitro expression of angiogenesis factors by prostate cancer cells . Urology. 51:1998;161-167.
33. Bowling M.K., Nelson J.B., Tong K.P., et al. Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB) (abstract). Proc Annu Meet Am Soc Clin Oncol. 15:1996;A43.
34. Daliani D., Finn L., Hodges S., et al. Interleukin-6 (IL-6) a marker of androgen-independent (AI) growth in prostatic carcinoma (PC).(abstract) . Proc Annu Meet Am Soc Clin Oncol. 16:1997;A1183.
35. Perry K.T., Anthony C.T., Case T., et al. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology. 49:1997;151-155.
36. Darbonne W.C., Rice G.C., Mohler M.A., et al. Red blood cells are the sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 88:1991;1362-1369.